FibromyalgiaNCT05149222
"REACT-FM-EXT": Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia: An Extension Study
A study testing Digital ACT in people with Fibromyalgia, run by Swing Therapeutics, Inc. at 1 site in United States.
Trial summary
This is an extension study of REACT-FM. The primary objective of the study is to assess the response to digital therapy in the treatment of fibromyalgia over an additional 9 months. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Fibromyalgia
- What is being tested?
- Digital ACT
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Nov 2021to 14 Apr 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant has completed participation in the REACT-FM study.
- Participant has completed 41 sessions within Tempo in the REACT-FM study and is willing and able to comply with all protocol-specified requirements.
- Participant has provided informed consent to participate.
- Participant continues to meet original safety criteria for the REACT-FM study.
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
About this study
This is an extension study of REACT-FM. The primary objective of the study is to assess the response to digital therapy in the treatment of fibromyalgia over an additional 9 months.
- Conditions
- Fibromyalgia
- Being tested
- Digital ACT
- Medical subject headings
- Fibromyalgia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital ACTDevice
This is a virtual, single-arm, non-significant risk study. Study participants will receive 9 months of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia.
| Study group | Role | What they receive |
|---|---|---|
| Digital Acceptance and Commitment Therapy (ACT) Arm | Other | Pragmatic Receives: Device: Digital ACT |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary efficacy endpoint is the response rate to Patient Global Impression of Change (PGIC).
PGIC scores included are: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse
Measured: 9 months
Secondary outcomes (7)
Revised Fibromyalgia Impact Questionnaire (FIQ-R) total score
FIQ-R total score ranges between 0-100 with a reduction in score indicating reduced fibromyalgia severity.
Measured: Enrollment to Month 9
Revised Fibromyalgia Impact Questionnaire (FIQ-R) symptoms domain score
FIQ-R symptoms domain score ranges between 0-50 with a reduction in score indicating reduced fibromyalgia symptoms.
Measured: Enrollment to Month 9
Revised Fibromyalgia Impact Questionnaire (FIQ-R) function domain score
FIQ-R function domain score ranges between 0-30 with a reduction in score indicating improved function.
Measured: Enrollment to Month 9
Revised Fibromyalgia Impact Questionnaire (FIQ-R) impact domain score
FIQ-R impact domain score ranges between 0-20 with a reduction in score indicating reduced fibromyalgia impact.
Measured: Enrollment to Month 9
Participant's self-reported average weekly pain score, recorded on an NRS scale
Average pain intensity score ranges between 0-10 with a reduction in score indicating a decrease in pain intensity.
Measured: Enrollment to Month 9
Participant's self-reported average weekly pain interference score, recorded on an NRS
Average pain interference score ranges between 0-10 with a reduction in score indicating a decrease in pain interference.
Measured: Enrollment to Month 9
Participant's self-reported weekly sleep interference score, recorded on an NRS scale
Average sleep interference score ranges between 0-10 with a reduction in score indicating a decrease in sleep interference.
Measured: Enrollment to Month 9
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2021
- Study start30 Nov 2021
- Primary completion14 Apr 2024
- Study completion14 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FibromyalgiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a virtual, single-arm, pragmatic, non-significant risk study. Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Swing Therapeutics, Inc.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Brian Keefe, MD, Principal investigator, Swing Therapeutics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05149222
- Sponsor's protocol ID
- Swing-003-EXT
- Status last verified
- Jul 2024
- First submitted
- 24 Nov 2021
- Last updated
- 16 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "REACT-FM-EXT": Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia: An Extension Study
- ClinicalTrials.gov ID
- NCT05149222
- Acronym / sponsor ID
- Swing-003-EXT
- Conditions
- Fibromyalgia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Swing Therapeutics, Inc.University, hospital or other
- Study start
- 30 Nov 2021 (actual)
- Primary completion
- 14 Apr 2024 (actual)
- Study completion
- 14 Apr 2024 (actual)
- First posted
- 8 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an extension study of REACT-FM. The primary objective of the study is to assess the response to digital therapy in the treatment of fibromyalgia over an additional 9 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a virtual, single-arm, pragmatic, non-significant risk study. Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia
| Arm | Type | Receives |
|---|---|---|
| Digital Acceptance and Commitment Therapy (ACT) Arm | Other | Device: Digital ACTPragmatic |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Participant has completed participation in the REACT-FM study.
- Participant has completed 41 sessions within Tempo in the REACT-FM study and is willing and able to comply with all protocol-specified requirements.
- Participant has provided informed consent to participate.
- Participant continues to meet original safety criteria for the REACT-FM study.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital ACTThis is a virtual, single-arm, non-significant risk study. Study participants will receive 9 months of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia. | Device | Digital Acceptance and Commitment Therapy (ACT) Arm |
Primary outcome
The primary efficacy endpoint is the response rate to Patient Global Impression of Change (PGIC).
Time frame: 9 months
PGIC scores included are: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse
7 secondary outcomes
Revised Fibromyalgia Impact Questionnaire (FIQ-R) total score
Time frame: Enrollment to Month 9
Revised Fibromyalgia Impact Questionnaire (FIQ-R) symptoms domain score
Time frame: Enrollment to Month 9
Revised Fibromyalgia Impact Questionnaire (FIQ-R) function domain score
Time frame: Enrollment to Month 9
Revised Fibromyalgia Impact Questionnaire (FIQ-R) impact domain score
Time frame: Enrollment to Month 9
Participant's self-reported average weekly pain score, recorded on an NRS scale
Time frame: Enrollment to Month 9
Participant's self-reported average weekly pain interference score, recorded on an NRS
Time frame: Enrollment to Month 9
Participant's self-reported weekly sleep interference score, recorded on an NRS scale
Time frame: Enrollment to Month 9
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2024.
- Swing Therapeutics WebsiteLink provided by the sponsor.
Related trials for Fibromyalgia
Not yet recruiting
Effects of Adding Vagal Neuromodulation to Manual Therapy in Women With Fibromyalgia
Fibromyalgia (FM) OR Fibromyalgia Syndrome, Manuel Therapy
Active, not recruiting
PEACE: Comparing Chronic Pain Treatment Options
Chronic Pain, Musculoskeletal Pain
Enrolling by invitation
Wearable Biofeedback Devices for Remote Physiotherapy and Rehabilitation
Arthritis, Fibromyalgia
Active, not recruiting
Relationships of Affect and Neuroinflammation With Clinical Pain in Veterans With Fibromyalgia
Fibromyalgia
Recruiting
Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome
Myofacial Pain, Myofacial Pain Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Brian Keefe, MD principal investigator
Swing Therapeutics
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Digital ACT in people with Fibromyalgia, run by Swing Therapeutics, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary efficacy endpoint is the response rate to Patient Global Impression of Change (PGIC). (time frame: 9 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2024.